Mockingbird Investment – Page 2 – Better returns through sharing ideas

August 2, 2024

Quiet Contrarian. Ep58: Trades for July 2024

Buys Vitura Health – VIT.ASX – I was initially skeptical of these guys, referring to them as the “party drug company”. But since then I have started to research, and am seeing building legitimacy in the use of MDMA and Psilocybin as mental health treatments. This may be a long long long hold, and a bit of a punt (derisked by...

Ideas

July 22, 2024

Quiet Contrarian. Ep 57: FY24 Reflection

Overall update – Story of the year I have done ok again this year. Not as good as previous, but still good, and still beating the market. FY24 Goals and Positioning Recap This was a year to try and continue the trends from last year. Maintain disciplined behaviour, do more research and process more companies. Portfolio Performance I beat the...

Ideas/Stories

July 15, 2024

Quiet Contrarian. Ep56: Trades for June 2024

Buys Quiet month, just rounding out the FY slowly. Cogstate Ltd – CGS.ASX – The Eli Lily drug has been having some effect in slowing progression, but hasn’t been as effective as people have hoped. Despite that I am still hopeful for treatments and interest in slowing/stopping Alzheimers. So I topped up a little bit of these guys. Lots of uncertainty,...

Ideas

June 3, 2024

Quiet Contrarian. Ep55: Trades for May 2024

Buys Reckon Ltd – RKN.ASX – Xero raised their prices again. Reckon One is the cheapest accounting software in that space. But, it’s very much hated by accountants (though I can’t tell how much of this is legacy from old versions of the software), however, the software gets very good reviews from it’s customers. The company still makes good money and...

Ideas

May 2, 2024

Quiet Contrarian. Ep54: Trades for April 2024

Sorry for not posting in March. I didn’t make any trades, and have been going through one of those patches where life just hurls things at you. Things have settled a bit and I should be back on schedule. Still not much action this month, but I made one trade. Sells IGO Ltd – IGO.ASX – They have been punished in...

Ideas

March 4, 2024

Quiet Contrarian. Ep53: Trades for February 2024

Buys Clinuvel Pharmaceuticals Ltd – CUV.ASX – Continuing to increase my position. Revenue growth is slowing as they reach the end of the growth trajectory for the initial use for the drug (EPP treatment, rare condition, orphan drug status). They are currently seeking new uses for Scenesse to treat 5 other conditions, and have increased operational costs to do this. On...

Stories

February 2, 2024

Quiet Contrarian. Ep52: Trades for January 2024

Buys Clinuvel Pharmaceuticals Ltd – CUV.ASX – They have a drug to treat severe phototoxicity (Scenesse), to my understanding they basically have a monopoly position in the market; and they are looking for new opportunities to increase sales by applying the drug to the treatment of other conditions (e.g. vitiligo). I bought on recent price weakness, which I think will be...

Stories

January 2, 2024

Quiet Contrarian. Ep 51: Half Year Portfolio Update 2024

Portfolio Performance I was surprised by the result. I felt like I’d been doing badly, but overall the portfolio has done well again, though it is split by region. In Australia (and overall) I have outperformed my benchmarks by ~8-10%, whilst in the US I underperformed by ~1%. Here’s a bit of background on the Benchmarks I’ve been using: I...

Stories